Document is current
Any future updates will be listed below
-
Authors
Rojas-Amaris, Natalia
Marenco-Flores, Ana
Barba, Romelia
Mendoza, Roberto
Patwardhan, Vilas
Bonder, Alan
- License Information
-
More Information
Article History
Accepted: 2 September 2025
First Online: 15 November 2025
Declarations
:
: Financial interests: Alan Bonder consults for Intercept Pharmaceuticals, Ipsen, ChemomAb Ltd., GSK, and Guidepoint. He has received a grant from Gilead Sciences. He has also been the primary investigator for trials sponsored by Gilead Sciences, Cara Therapeutics, Mirum Pharmaceuticals Inc., CymaBay Therapeutics Inc., Genfit, ChemomAb Ltd., and Intercept Pharmaceuticals. He has received royalties or holds licenses from UpToDate and DynaMed. He serves on the editorial committee of DynaMed, and the Clinical Liver Disease Journal for AASLD, and has given expert testimony for Expert Review, Inc.. He has also served as a medical reviewer for Pfizer. The other authors do not have conflicts of interest relevant to this work.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
